Differences in treatment patterns among patients with castration-resistant prostate cancer treated by oncologists versus urologists in a US managed care population

References

• MaxWRiceDPSungHYMichelMBreuerWZhangXThe economic burden of prostate cancer, California, 1998Cancer20029411 2906291312115378
   PubMed Web of Science ®Google Scholar
• National Cancer InstituteSEER stat fact sheets: prostate Available at: http://www.seer.cancer.gov/statfacts/html/prost.html. Accessed May 18, 2011.
   Google Scholar
• JemalASiegelRXuJWardECancer statistics, 2010Ca Cancer J Clin201060527730020610543
   PubMed Web of Science ®Google Scholar
• AltekruseSFKosaryCLKrapchoMSEER cancer statistics review, 1975–2007National Cancer InstituteBethesda MD Available at: http://seer.cancer.gov/csr/1975_2007/. Accessed May 18, 2011.
   Google Scholar
• QuinnMBabbPPatterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisonsBJU Int200290216217312081758
   PubMed Web of Science ®Google Scholar
• ChodakGProstate cancer: epidemiology, screening, and biomarkersRev Urol20068Suppl 2S3S817021639
   PubMedGoogle Scholar
• JohanssonJEHolmbergLJohanssonSBergstromRAdamiHOFifteen-year survival in prostate cancer: a prospective, population-based study in SwedenJAMA199727764674719020270
   PubMed Web of Science ®Google Scholar
• American Society of Clinical OncologyProstate cancerCancer. Net. Available at: http://www.cancer.net/patient/Cancer+Types/Prostate+Cancer. Accessed May 18, 2011.
   Google Scholar
• American Cancer SocietyWhat is prostate cancer? Information and resources for cancer: breast, colon, prostate, lung and other forms Available at: http://www.cancer.org/Cancer/ProstateCancer/DetailedGuide/prostate-cancer-key-statistics. Accessed May 18, 2011.
   Google Scholar
• SerugaBOcanaATannockIFDrug resistance in metastatic castration-resistant prostate cancerNat Rev Clin Oncol201181122320859283
   PubMed Web of Science ®Google Scholar
• National Cancer InstituteSEER relative survival rates by survival time. By Cancer Site, prostate, all ages, all races, male, 1988–2004 Available at: http://seer.cancer.gov/faststats/selections.php#Output. Accessed May 18, 2011.
   Google Scholar
• PSA Rising. Provenge vaccine “significantly improves” survival in men with advanced prostate cancer. [Press release. February 17, 2005]. Available at: http://www.psa-rising.com/med/immun/provenge-05.htm. Accessed May 18, 2011.
   Google Scholar
• National Comprehensive Cancer Network [NCCN]Prostate cancer. NCCN clinical practice guidelines in oncology, v.3.2010Fort Washington, PA Available at: http://www.nccn.org/professionals/physician_gls/PDF/prostate.pdf. Accessed May 18, 2011.
   Google Scholar
• JamesNDCatyABorreMSafety and efficacy of the specific endothelin A receptor antagonist ZD4054 in patients with hormone resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trialEur Urol20095551112112319042080
   PubMed Web of Science ®Google Scholar
• SaadFKarakiewiczPPerrottePThe role of bisphosphonates in hormone-refractory prostate cancerWorld J Urol2005231141815666171
   PubMed Web of Science ®Google Scholar
• TannockIFde WitRBerryWRDocetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancerN Engl J Med2004351151502151215470213
   PubMed Web of Science ®Google Scholar
• QuiltyPMKirkDBolgerJJA comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancerRadiother Oncol199431133407518932
   PubMed Web of Science ®Google Scholar
• FitzpatrickJMAndersonJSternbergCNOptimizing treatment for men with advanced prostate cancer: expert recommendations and the multidisciplinary approachCrit Rev Oncol Hematol200868Suppl 1S9S2218723368
   PubMed Web of Science ®Google Scholar
• PetrylakDPTangenCMHussainMHDocetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancerN Engl J Med2004351151513152015470214
   PubMed Web of Science ®Google Scholar
• AlemayehuBBuysmanEParryDBeckerLNathanFEconomic burden and healthcare utilization associated with castration-resistant prostate cancer in a commercial and Medicare Advantage US patient populationJ Med Econ201013235136120491610
   PubMedGoogle Scholar
• BeerTMBerryWWersingerEMWeekly docetaxel in elderly patients with prostate cancer: efficacy and toxicity in patients at least 70 year of age compared with patients younger than 70 yearsClin Prostate Cancer20032316717215040860
   PubMedGoogle Scholar
• SchillingPJFormation of combined urology and radiation oncology practices: objective data from radiation oncologists for rationaleAm J Clin Oncol8272010 [Epub ahead of print]
   Google Scholar
• CrawfordEDThe role of the urologist in treating patients with hormone-refractory prostate cancerRev Urol20035Suppl 2 S48S5216986047
   PubMedGoogle Scholar
• MontagutCAlbanellJBellmuntJProstate cancer. Multidisciplinary approach: a key to successCrit Rev Oncol Hematol200868Suppl 1S32S3618723370
   PubMed Web of Science ®Google Scholar
• JangTLBekelmanJELiuYPhysician visits prior to treatment for clinically localized prostate cancerArch Intern Med20101705 44045020212180
   PubMedGoogle Scholar
• TanejaSSA multidisciplinary approach to the management of hormone-refractory prostate cancerRev Urol20035Suppl 2S53S5916986048
   PubMedGoogle Scholar
• BracardaSLogothetisCSternbergCNCurrent and emerging treatment modalities for metastatic castration-resistant prostate cancerBJU Int2011107Suppl 2132021382150
   PubMed Web of Science ®Google Scholar
• SpencerBAMillerDCLitwinMSVariations in quality of care for men with early-stage prostate cancerJ Clin Oncol20082622 3735374218669460
   PubMed Web of Science ®Google Scholar
• CooperbergMRSpecialist visits (urologist, radiation oncologist, medical oncologist) are strongly associated with treatment received for prostate cancer in the USAEvid Based Med2010153959620522696
   PubMedGoogle Scholar
• MillerDCSpencerBARitcheyJTreatment choice and quality of care for men with localized prostate cancerMed Care2007455 40140917446826
   PubMed Web of Science ®Google Scholar
• North West Uro-Oncology GroupA preliminary report on a patient-preference study to compare treatment options in early prostate cancerBJU Int200290325325612133061
   PubMed Web of Science ®Google Scholar
• GroverSAZowallHCoupalLKrahnMDProstate cancer: 12. The economic burdenCMAJ1999160568569010102004
   PubMed Web of Science ®Google Scholar
• SkolarusTAZhangYMillerDCWeiJTHollenbeckBKThe economic burden of prostate cancer survivorship careJ Urol2010184253253820620413
   PubMed Web of Science ®Google Scholar
• RoehrigCMillerGLakeCNational health spending by medical condition,1996–2005Health Aff (Millwood)2009282w35819240056
   PubMed Web of Science ®Google Scholar
• YabroffKRLamontEBMariottoACost of care for elderly cancer patients in the United StatesJ Natl Cancer Inst20081009 63064118445825
   PubMed Web of Science ®Google Scholar
• US Department of Labor, Bureau of Labor StatisticsConsumer Price Index Chained Consumer [Price Index for all urban consumers (C-CPI-U) 1999–2008], Medical Care. Series ID: SUUR0000SAM. Available at: http://data.bls.gov/cgi-bin/surveymost?su. Accessed May 18, 2011.
   Google Scholar
• LinDYLinear regression analysis of censored medical costsBiostatistics200011354712933524
   PubMedGoogle Scholar
• KrupskiTLFoleyKABaserOHealthcare cost associated with prostate cancer, androgen deprivation therapy and bone complicationsJ Urol20071784 Pt 11423142817706711
   PubMed Web of Science ®Google Scholar
• WilsonLSTesoroRElkinEPCumulative cost pattern comparison of prostate cancer treatmentsCancer20071093 51852717186528
   PubMed Web of Science ®Google Scholar
• PensonDFMoulJWEvansCPThe economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: findings from a retrospective analysis of health plan dataJ Urol20041716 Pt 12250225415126796
   PubMed Web of Science ®Google Scholar
• CrawfordEDBlackLEaddyMKrueppEJA retrospective analysis illustrating the substantial clinical and economic burden of prostate cancerProstate Cancer Prostatic Dis2010132 16216720125121
   PubMed Web of Science ®Google Scholar
• KrahnMDZagorskiBLaporteAHealthcare costs associated with prostate cancer: estimates from a population-based studyBJU Int2010105333834619594734
   PubMed Web of Science ®Google Scholar
• Engel-NitzNMAlemayehuBNathanFParryDVariations in chemotherapy treatment by oncologists and urologists for patients with castration-resistant prostate cancer (CRPC)Poster presented at the Academy of Managed Care Pharmacy (AMCP) Annual MeetingSt Louis, MOOctober 13–15, 2010
   Google Scholar